Hypothesis: Causes of Type 2 Diabetes in Progeroid Werner Syndrome

Lynne S. Cox*

Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK

Abstract: The premature ageing Werner syndrome (WS) is characterized by the early onset of many age related phenotypes, including graying of hair, cataracts, atherosclerosis, cancer and type 2 diabetes. Type 2 diabetes (DM2) is the loss of blood glucose homeostasis, due to insulin resistance and a failure of acute glucose-stimulated insulin secretion (GSIS) by pancreatic β cells. Early compensation for insulin resistance usually occurs through increased insulin secretion consequent on increased β cell mass, requiring proliferation of β cells; DM2 progresses if there is failure of compensation. How loss of the WRN DNA helicase/exonuclease in WS contributes to DM2 has long been a puzzle. Loss of function mutations in WRN result in problems with DNA replication, repair and recombination, consequential genomic instability and premature onset of cellular senescence. Here, I suggest that the high prevalence of DM2 in WS is a consequence of senescence of WS β cells, with islet cells undergoing highly premature failure of the hyperproliferative compensatory stage, rapidly leading to late stage diabetes. The additional contribution to DM2 progression by pro-inflammatory cytokines is discussed.

WERNER SYNDROME

Loss of the WRN helicase/exonuclease results in the premature ageing Werner’s syndrome, recapitulating many of the features of normal ageing [1]. Whilst WS patients usually display short stature, failure of the pubertal growth spurt, very low body mass index and loss of subcutaneous body fat, they also suffer from altered triglyceride metabolism and significant abdominal fat deposition, together with a very high incidence of atherosclerosis and arteriosclerosis [2]. In addition, patients show insulin resistance, accompanied by low levels of adiponectin and high circulating levels of plasma TNF-α [3, 4]; type 2 diabetes mellitus (DM2) is a highly penetrant phenotype [2]. Thus the majority of Werner syndrome patients develop clinically important DM2, and associated acceleration of atherosclerosis.

How does the loss of a single protein, WRN, lead to altered lipid and glucose metabolism and a strong predisposition to develop type 2 diabetes? In vitro, the WRN protein has been characterized as a 3′-5′ helicase of the RecQ family [5] and it also possesses a 3′-5′ exonuclease activity within an N terminal domain unique amongst the RecQ family [6]. Cultured human WS fibroblasts and lymphoblastoid cells show very premature onset of replicative senescence, with some WS patient fibroblast lines undergoing senescence after only ~20 population doublings, compared with the 50-60 of normal fibroblasts [7]. This premature senescence is associated with significant defects in DNA repair and recombination, and particularly a problem with replication fork progression over unusual DNA structures [8-10] caused either by endogenous template elements such as fragile X sites [11, 12] or by exogenous DNA damage (reviewed in [13]). The resulting DNA instability appears to trigger a stress pathway mediated through p38 MAP kinase, together with expression of genes such as p16INK4a/6 and p21CDKN1 that trigger and maintain the senescent state (reviewed in [14]). Inhibiting the stress signaling pathway through use of inhibitors of p38 kinase (MAPK, also known as stress-associated protein kinase, p38 SAPK) such as SB203580 restores an essentially normal cell morphology and proliferation kinetics to Werner’s syndrome fibroblasts [15], emphasizing the importance of stress and DNA damage signaling in the pathology of WS. Because of the rarity of the disease, the senescent phenotype of many other WS cell types is unknown, though it is likely that many rapidly proliferating cell types will, like fibroblasts and lymphoblastoid cells, progress rapidly to senescence.

STAGES IN DEVELOPMENT OF TYPE 2 DIABETES

Type 2 diabetes (DM2), also known as non-insulin dependent diabetes (NIDD) usually occurs gradually over the course of years, with insulin resistance preceding development of the full clinical disease. Five stages have been proposed in disease progression (reviewed in [16]). In response to insulin resistance and mild glycaemia, a compensatory stage 1 occurs with increased insulin production arising predominantly as a consequence of increased β cell mass via proliferation (also known as β cell replication), neogenesis and hypertrophy of β cells. Stage 2 represents a stable adaptation phase in which true glucose regulation is not fully maintained and where changes to β cell activity and phenotype occur, including significant shifts in gene expression leading to dedifferentiation and loss of acute glucose-stimulated insulin secretion (GSIS). Stage 3 is generally called a decompensation phase, with the suggestion that β cell mass becomes inadequate, although a recent systems modeling approach suggests that this so-called decompensation stage actually represents a phase when the system is still trying to compensate for ongoing functional and cellular loss (Armin Rashid, pers. comm.) by hyperproliferation of pancreatic islet cells to provide more insulin; failure of this hyperproliferative stage leads to true hypoproliferative decomp-
pensation stage 4. Although in autoimmune type 1 diabetes, this can rapidly progress to stage 5 with ketosis, stage 4 is usually stable in DM2. Loss of up to half of the β cell mass has been observed post mortem in patients with DM2 [17] and rodent studies show major dedifferentiation [18]. Although increased apoptosis of β cells is often assumed to account for loss of cell mass, inadequate β cell replication or neogenesis with normal rates of apoptosis could equally contribute to a decrease in cell mass, since this is normally maintained through fine balance between cell birth (proliferation and neogenesis) and cell death (apoptosis and, to a lesser extent, necrosis) [16]. Indeed, enhanced apoptosis was not observed in partially pancreatectomized rats in stage 4 diabetes [19].

To compensate for a decrease in β cell number or diminished cell function (e.g., on dedifferentiation of pre-existing β cells), there is a requirement for rapid β cell proliferation. However, when cultured in vitro, β cells proliferate poorly, reaching a state of replicative senescence within only 10-15 population doublings, with increased SA-β gal staining, shortened telomeres and increased expression of p16INK4a [20], all hallmarks of senescence. Interestingly, ectopic expression of hTERT, while restoring telomerase activity in the β cells, did not rescue them from senescence [20]. Normal β cells therefore undergo rapid senescence in vitro, and it is likely that a similar process occurs in vivo [21]. If the cells are additionally lacking WRN helicase/exonuclease and thus even more prone to senesce early, as in WS, it is highly likely that there will be a premature inability to compensate, with rapid progression to the more clinically severe later decapsulation stages of diabetes. This could account for the high incidence of DM2 in WS patients.

**DRIVERS OF SENESCENCE IN WS β CELLS**

The altered lipid and glucose metabolism observed in DM2 may in part be consequent on peroxisome proliferator-activated receptor (PPAR) dysregulation [22-24], and further exacerbated by inflammation and oxidative damage. Indeed, a role for inflammatory cytokines, particularly interleukin-6, has been demonstrated in the pathogenesis of DM2 in WS [25]. Recently, IL-6, among other inflammatory cytokines, has been shown to relay signals for oncogene-induced senescence [26, 27]. Moreover, WS patients show high levels of circulating inflammatory cytokines such as TNF-α [3]. Inflammation contributing to tissue ageing is highly likely [28], and such inflammation leads to formation of reactive oxygen species at high local concentrations [29]. Interestingly, WS cells are hypersensitive to oxidative damage not simply at the level of DNA repair [30]. Oxidative damage may drive senescence through telomere shortening [31], and it has been observed that white blood cells from diabetic patients with microalbuminuria (indicative of oxidative damage to the kidney) have shorter telomeres than those from diabetic patients without oxidative kidney damage [32]. However, is unlikely that such telomere shortening contributes significantly to β cell senescence, since, as noted above, hTERT expression does not extend the proliferative capacity of β cells in vitro [20]. A discussion of senescence of other cells such as endothelial progenitor cells, whilst probably important in the overall pathogenesis of DM2, is beyond the scope of this paper.

A combination of accumulated DNA damage, inflammation and oxidative stress resulting from altered metabolism, and high levels of stress signaling are probable drivers of cellular senescence (reviewed in [1, 14]). The greatly accelerated onset of cellular senescence in Werner’s syndrome associated with early loss of proliferative capacity therefore means that the early response to insulin resistance i.e. hyperproliferation of islet cells, is therefore likely to be limited. Interestingly, mice mutant for the cyclin dependent kinase Cdk4 show normal early development of the pancreas, but islet function requires Cdk4, with null mice showing insulin resistance [33]. This is entirely consistent with a requirement for proliferation in the development and function of the pancreas: human WS patients show stunted overall growth, as do the Cdk4 mice, and perhaps they share also incomplete growth and inadequate functioning of the pancreas due to a deficit in cell proliferation caused, in the case of WS, by premature cell senescence. Similarly, cyclin D2 null mice show a post-natal deficit in pancreatic β cell replication and associated (mild) diabetes [34]. Developmental deficits in the pancreas cannot therefore be ruled out at this stage as a significant factor in subsequent diabetes in WS.

Given the imbalance of lipid metabolism in WS patients (as modeled in mice mutant for the helicase domain of WRN - [35]), type 2 diabetes is an inherent risk. Mice null for WRN fed on a diabetogenic diet do indeed succumb to diabetes very readily [36], showing fatty change in the liver and pancreatic hyperproliferation. What is not yet clear is whether such mice show a rapid failure of the hyperproliferative phase due to the early onset of senescence, as predicted here. There is some conflict in the literature as to the impact of various naturally occurring polymorphisms of WRN in terms of DM2 predisposition; in a Japanese study, the Cys1367Arg polymorphism protects against diabetes [37], whilst in Chinese patients it has been reported that the same polymorphism is associated with early onset of diabetes [38]. Whatever the impact of the polymorphism (and it may be genuinely different in different genetic backgrounds), it is clear that loss of WRN function strongly predisposes to the development of insulin resistance and type 2 diabetes.

**TREATING DIABETES IN WS**

Various complications associated with insulin resistance including dyslipidemia and visceral fat deposition are likely to contribute to the high risk of cardiovascular disease in WS [1, 2]. Treating WS patients with the PPARγ agonist pioglitazone, which regulates transcription of insulin-sensitive genes (including MAP kinases, glucose-6-phosphatase, pyruvate dehydrogenase and NAD(P)H dehydrogenase, to name only a few - [39]) leads to beneficial changes in fat distribution and serum adiponectin levels, together with a decrease in insulin resistance [3, 4, 40, 41]. Stress kinase signalling through the p38 MAP kinase pathway is elevated in diabetes (and also induced in response to high glucose concentrations - [42]). Given the remarkable impact of MAP kinase inhibitor SB203580 in restoring a normal proliferative phenotype to WS fibroblasts [15], it is certainly worth testing in vivo-tolerated analogues such as BIRB 796 [43] in murine models of WS to determine whether they positively impact on pancreatic function through restoration of islet cell proliferation. In this context, it is worth noting that BIRB 796 treatment of humans leads to a significant reduction in TNF-
α [44], a key inflammatory cytokine that probably contributes to DM2 pathogenesis in WS [3, 25]. Thus p38 MAPK inhibition might result both in enhanced β cell proliferation and a decrease in the inflammatory load on the pancreas which would otherwise drive senescence. However, as a note of caution, is possible that upregulation of p38 MAPK may be important in preventing islet β cell apoptosis [45], and as such, its inhibition may lead to loss of the very cells that are required to prevent development of DM2.

ACKNOWLEDGEMENTS

I thank Dr Penelope Mason for helpful comments on the manuscript. This work was supported by the Biotechnology and Biological Sciences Research Council [grant numbers BB/E000924/1 and BB/E016995/1].

ABBREVIATIONS

Cdk4 = cyclin dependent kinase 4
DM2 = diabetes mellitus type 2
GSIS = glucose stimulated insulin secretion
IL6 = interleukin 6
MAPK = mitogen activated protein kinase
PPAR = peroxisome proliferator-activated receptor
SAPK = stress associated protein kinase
TNFα = tumour necrosis factor alpha
WRN = Werner syndrome helicase/exonuclease
WS = Werner syndrome

REFERENCES


[38] Luo, Y, Ji, L, Han, X. The role of Werner's syndrome gene in the genetic susceptibility to the type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 2000; 80: 360-1.


